Incyte’s previously disclosed phase 3 win in relapsed or refract | In the phase 3 inMIND study, Monjuvi—added to Bristol ...

"Full House" star Dave Coulier, 65, has been diagnosed with stage 3 non-Hodgkin lymphoma, the actor revealed in an exclusive ...

In turn, primary care experts called for a PET scan, CT scan and biopsy. Results then showed he had a “very aggressive” form ...

Recent news reveals Full House star Dave Coulier is battling stage 3 lymphoma, drawing attention and concern from fans ...

Dave Coulier has been diagnosed with Stage 3 non-Hodgkin lymphoma. The Full House alum shared the news on TODAY on Wednesday, ...

Dave Coulier was shocked to learn he has stage 3 non-Hodgkin lymphoma. He opens up to PEOPLE exclusively about his diagnosis and how he has been leaning on family and humor through his cancer journey.

Adcendo joins a growing group of biotechs working to usher the next generation of antibody-drug conjugates to the market.

French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma (B-NHL). | French ...

The actor said the blood cancer is "very treatable" and expects a "total remission." Full House Star Dave Coulier Diagnosed ...

Incyte (Nasdaq: INCY) today announced that the Company will present new data from across its oncology portfolio at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego.

Fate Therapeutics (FATE) presented initial clinical and translational data from the company’s Phase 1 study of FT522 in relapsed / refractory ...

Phase 1 Basket Study for B Cell-mediated Autoimmune Diseases to Assess FT522 as Add-on to Standard-of-care Induction and Maintenance Regimens ...